EQ on Nasdaq

Equillium, Inc.

We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Biofrontera Inc., Verona Pharma or Enveric Biosciences, Inc., or pick any stock.

  • TickerEQ on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersLaJolla, United States2
  • Incorporated inDE3
  • Business address2223 Avenida De La Playa, Suite 105, La Jolla, Ca 920373
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300OC7SSPSNNGHE642
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 63428972

See how the biggest companies compare on our leaderboards

We are a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. Our primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

-20.1%Operating margin5
-19.6%Net margin5
13.9%Revenue growth, 20245
-42.3%Return on equity5
-$19.1MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Other costs99¢$40.7M
  • Income tax1¢$361.0K

Out of $41.1M in revenue.5 The company lost money this year.

Financial statements

Revenue675$41.1M in 2024+161% since 2022
0$20.0M$40.0M$60.0M2022: $15.8M$15.8M20222023: $36.1M$36.1M2023+129%2024: $41.1M$41.1M2024+14%
Operating income8910675-$8.3M in 2024−69% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$26.7M-$26.7M20192020: -$29.5M-$29.5M2020+11%2021: -$37.8M-$37.8M2021+28%2022: -$62.1M-$62.1M2022+64%2023: -$14.5M-$14.5M2023−77%2024: -$8.3M-$8.3M2024−43%
Net income8910675-$8.1M in 2024−68% since 2019
-$80.0M-$60.0M-$40.0M-$20.0M02019: -$25.6M-$25.6M20192020: -$29.8M-$29.8M2020+16%2021: -$39.1M-$39.1M2021+31%2022: -$62.4M-$62.4M2022+60%2023: -$13.3M-$13.3M2023−79%2024: -$8.1M-$8.1M2024−40%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$41.1M
Research and development$12.8M$37.4M
General and administrative$10.8M$11.9M
Total operating expenses$23.6M$49.4M
Loss from operations-$23.6M-$8.3M
Interest income$833.0K$1.4M
Other income (expense), net$403.0K-$818.0K
Total other income, net$1.2M$563.0K
Loss before income tax expense-$22.4M-$7.7M
Income tax expense$0$361.0K
Net loss-$22.4M-$8.1M
Unrealized loss on available-for-sale securities, net-$3.0K-$15.0K
Foreign currency translation (loss) gain-$415.0K$656.0K
Total other comprehensive (loss) income, net-$418.0K$641.0K
Comprehensive loss-$22.8M-$7.4M
Net loss per share, basic-$0.39-$0.23
Net loss per share, diluted-$0.39-$0.23
Weighted-average number of common shares outstanding, basic57.3M shares35.4M shares
Weighted-average number of common shares outstanding, diluted57.3M shares35.4M shares

Compare Equillium, Inc. with another company

Leadership

Who has led Equillium, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel Bradbury2018–2019
  2. Bruce D. Steel2020–now

Chair

  1. Daniel Bradbury2020–now

President

  1. Bruce D. Steel2018–now

Chief financial officer

  1. Jason A. Keyes2018–now

Chief operating officer

  1. Christine Zedelmayer2020–now
20202025
Board members and other officers (13)

Timeline

  1. May 21, 2020New chief executive Bruce D. Steel becomes CEO14
  2. Oct 11, 2018New chief executive Daniel Bradbury becomes CEO15

Filings

276 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 62 major events, 101 insider forms, 17 large holders, 76 other. The latest 20:

  1. Oct 5, 20268-K EDGAR
  2. Aug 13, 202610-Q EDGAR
  3. Aug 13, 20268-K EDGAR
  4. Aug 13, 2026SCHEDULE 13G EDGAR
  5. Aug 12, 2026SCHEDULE 13G/A EDGAR
  6. Jun 5, 2026144 EDGAR
  7. Jun 5, 20264 EDGAR
  8. Jun 5, 20264 EDGAR
  9. Jun 4, 2026144 EDGAR
  10. May 29, 20264 EDGAR
  11. May 29, 20264 EDGAR
  12. May 29, 20264 EDGAR
  13. May 29, 20264 EDGAR
  14. May 29, 20264 EDGAR
  15. May 29, 20264 EDGAR
  16. May 29, 20264 EDGAR
  17. May 29, 20268-K EDGAR
  18. May 27, 2026144 EDGAR
  19. May 15, 2026SCHEDULE 13G/A EDGAR
  20. May 15, 2026SCHEDULE 13G/A EDGAR

The 276 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

29 open-market trades by officers, directors and large owners since October 2021: 0 buys and 29 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 5, 2026Zedelmayer ChristineSr. Vice President and COOSale14,584$2.93$42.7KForm 4
Jun 5, 2026Connelly StephenPresident and CSOSale30,975$2.94$91.1KForm 4
Jun 4, 2026Connelly StephenPresident and CSOSale200,000$3.16$632.0KForm 4
May 28, 2026Tom PennyPrincipal Accounting OfficerSale65,000$2.95$191.8KForm 4
May 28, 2026Zedelmayer ChristineSr. Vice President and COOSale86,012$2.80$240.7KForm 4
May 27, 2026Zedelmayer ChristineSr. Vice President and COOSale9,821$2.70$26.5KForm 4
Mar 13, 2026Zedelmayer ChristineSr. Vice President and COOSale120,312$2.50$300.8KForm 4
Mar 9, 2026Zedelmayer ChristineSr. Vice President and COOSale181,219$2.00$362.4KForm 4
Feb 19, 2026Zedelmayer ChristineSr. Vice President and COOSale185,937$1.76$327.9KForm 4
Feb 19, 2026Zedelmayer ChristineSr. Vice President and COOSale185,937$1.76$327.9KForm 4
Jan 8, 2026Tom PennyPrincipal Accounting OfficerSale6,533$1.29$8.4KForm 4
Dec 23, 2025Zedelmayer ChristineSr. Vice President and COOSale100,000$1.50$150.0KForm 4
Dec 15, 2025Zedelmayer ChristineSr. Vice President and COOSale11,900$1.31$15.6KForm 4
Dec 12, 2025Zedelmayer ChristineSr. Vice President and COOSale23,804$1.34$31.9KForm 4
Nov 25, 2025Zedelmayer ChristineSr. Vice President and COOSale8,098$0.95$7.7KForm 4
Jan 23, 2025Keyes Jason AChief Financial OfficerSale10,000$0.65$6.5KForm 4
Nov 14, 2024Keyes Jason AChief Financial OfficerSale10,000$0.70$7.0KForm 4
Oct 28, 2024Zedelmayer ChristineSr. Vice President and COOSale15,000$1.25$18.8KForm 4
Oct 28, 2024Tom PennyPrincipal Accounting OfficerSale2,835$1.25$3.5KForm 4
Oct 25, 2024Tom PennyPrincipal Accounting OfficerSale683$1.25$854Form 4

All 29 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 60. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Jupiter Topco LLC6,494,571$20.7M0.0%New
Decheng Capital LLC4,447,308$14.2M1.9%No change
Affinity Asset Advisors, LLC4,100,000$13.1M0.7%+2,873,690
ADAR1 Capital Management, LLC3,758,569$12.0M0.6%+31,910
Aberdeen Group plc3,631,659$11.6M0.0%+278,822
Woodline Partners LP3,500,901$11.2M0.0%No change
Ra Capital Management, L.P.3,096,336$9.9M0.1%No change
Stempoint Capital LP2,016,607$6.5M1.1%New
Vanguard Capital Management LLC1,822,812$5.8M0.0%+38,340
Eversept Partners, LP1,520,824$4.9M0.3%+21,831
Adage Capital Partners Gp, L.l.c.1,390,253$4.4M0.0%−3,939,163
Renaissance Technologies LLC637,617$2.0M0.0%−19,347
Exome Asset Management LLC552,956$1.8M1.1%New
DG Capital Management, LLC463,396$1.5M0.6%New
Diadema Partners LP400,282$1.3M0.5%−33,562
Geode Capital Management, LLC381,175$1.2M0.0%+2,362
Balyasny Asset Management L.P.344,409$1.1M0.0%−1,294,361
Tudor Investment Corp Et Al320,100$1.0M0.0%+300,000
Ikarian Capital, LLC303,555$971.4K0.2%No change
BlackRock, Inc.285,409$913.3K0.0%+157,557
Boothbay Fund Management, LLC284,330$909.9K0.0%+191,119
Cantor Fitzgerald, L. P.218,124$698.0K0.0%−44,519
Two Sigma Investments, LP206,853$661.9K0.0%−39,320
Vanguard Fiduciary Trust Co190,810$610.6K0.0%+1,280
State Street Corp174,060$557.0K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41